Kereos

Kereos, Inc. is a biopharmaceutical company based in Saint Louis, Missouri, specializing in the development of targeted molecular imaging agents and therapeutics aimed at detecting and treating cancer and cardiovascular diseases. Established in 1999, Kereos utilizes a nanoscale drug delivery technology that enhances the targeting and efficacy of various therapeutic compounds, including existing drugs, new candidates, and those that may be too toxic or fragile for conventional delivery methods. The company's product portfolio includes KER-1001, a cancer therapeutic that combines paclitaxel with a targeted nanodroplet, KER-1002, which integrates a natural anti-tumor agent, and KER-1003, known for its anti-angiogenic properties. Additionally, Kereos offers diagnostic solutions such as KER 0001, designed to detect angiogenesis. The company also collaborates with pharmaceutical and imaging firms to further develop its MRI agents and targeted chemotherapeutics for solid tumors and cardiovascular applications.